Chaoyang Deyuan Pharmaceutical Co., Ltd.

This study aimed to study the pharmacokinetic characteristics of a single fasting and postprandial oral administration of sacubitril-valsartan sodium tablets [200 mg (sacubitril 97 mg/valsartan 103 mg)] licensed and produced by Liaoning Xinshanyuan Pharmaceutical Co., Ltd. in healthy subjects; using sacubitril-valsartan sodium tablets [Noxinto®, 200 mg (sacubitril 97 mg/valsartan 103 mg)] licensed by Novartis Pharma Schweiz AG and produced by Novartis Farma S.p.A. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, to evaluate the human bioequivalence of the two preparations, and to observe the safety of the two preparations in healthy subjects.

This study aimed to investigate the pharmacokinetic characteristics of dapagliflozin tablets (10 mg) produced by Liaoning Xinshanyuan Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using dapagliflozin tablets (Andatang®, 10 mg) produced by AstraZeneca Pharmaceuticals LP as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.

This study aimed to study the pharmacokinetic characteristics of clopidogrel bisulfate tablets (75 mg) developed and produced by Liaoning Xinshanyuan Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using clopidogrel bisulfate tablets (Plavix®, 75 mg) licensed and produced by Sanofi (Hangzhou) Pharmaceutical Co., Ltd. as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.